{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:34:12Z","timestamp":1791297252797,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jsbmb.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T09:05:44Z","timestamp":1395565544000},"page":"207-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"special_numbering":"C","title":["An overview of current and emerging SERMs"],"prefix":"10.1016","volume":"143","author":[{"given":"Barry S.","family":"Komm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1124\/pr.58.4.8","article-title":"International Union of Pharmacology. LXIV. Estrogen receptors","volume":"58","author":"Dahlman-Wright","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0010","first-page":"370","article-title":"Oestrogen receptors in breast cancer: basic mechanisms and clinical implications","author":"Williams","year":"2013","journal-title":"Ecancermedicalscienc"},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/13697137.2012.688079","article-title":"The evolution of selective estrogen receptor modulators in osteoporosis therapy","volume":"15","author":"Hadji","year":"2012","journal-title":"Climacteric"},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0020","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0025","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1210\/en.2003-1481","article-title":"Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats","volume":"145","author":"Ke","year":"2004","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.jsbmb.2014.03.003_bib0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1096\/fasebj.10.8.8666168","article-title":"Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats","volume":"10","author":"Sato","year":"1996","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.bjp.0707232","article-title":"Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro","volume":"151","author":"Michael","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"issue":"15","key":"10.1016\/j.jsbmb.2014.03.003_bib0045","first-page":"3867","article-title":"A potent specific pure antiestrogen with clinical potential","volume":"51","author":"Wakeling","year":"1991","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0050","first-page":"1870","article-title":"Species-specific pharmacology of antiestrogens: role of metabolism","volume":"46","author":"Jordan","year":"1987","journal-title":"Fed. Proc."},{"issue":"16","key":"10.1016\/j.jsbmb.2014.03.003_bib0055","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/jm980048b","article-title":"Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist\/antagonist, CP-336156, a diaryltetrahydronaphthalene","volume":"41","author":"Rosati","year":"1998","journal-title":"J. Med. Chem."},{"issue":"4\/5","key":"10.1016\/j.jsbmb.2014.03.003_bib0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jnci\/88.2.123","article-title":"Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid","volume":"88","author":"Anzano","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0070","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/sonc.2001.23492","article-title":"Tamoxifen to raloxifene and beyond","volume":"28","author":"O\u2019Regan","year":"2001","journal-title":"Semin. Oncol."},{"issue":"13","key":"10.1016\/j.jsbmb.2014.03.003_bib0080","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","article-title":"Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer","volume":"326","author":"Love","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0085","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","article-title":"Endometrial pathologies associated with postmenopausal tamoxifen treatment","volume":"94","author":"Cohen","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.jsbmb.2014.03.003_bib0095","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2000.18.17.3172","article-title":"Selective estrogen receptor modulators: structure, function, and clinical use","volume":"18","author":"Osborne","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.jsbmb.2014.03.003_bib0100","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1476-5381.1986.tb10174.x","article-title":"Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro","volume":"87","author":"Jordan","year":"1986","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.jsbmb.2014.03.003_bib0115","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1016\/S0021-9258(18)32484-0","article-title":"An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro","volume":"258","author":"Lieberman","year":"1983","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0120","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.0680453","article-title":"Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response","volume":"68","author":"Jordan","year":"1976","journal-title":"J. Endocrinol."},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0130","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","article-title":"Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata","volume":"12","author":"Jordan","year":"1976","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/bjs.1800690302","article-title":"Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors","volume":"69","author":"Wilson","year":"1982","journal-title":"Br. J. Surg."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0140","first-page":"376P","article-title":"The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat (proceedings)","volume":"64","author":"Jordan","year":"1978","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","article-title":"Effects of anti-estrogens on bone in castrated and intact female rats","volume":"10","author":"Jordan","year":"1987","journal-title":"Breast Cancer Res. Treat."},{"issue":"18","key":"10.1016\/j.jsbmb.2014.03.003_bib0150","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00198-011-1775-y","article-title":"Individualizing osteoporosis therapy","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-200060020-00013","article-title":"Raloxifene: a review of its use in postmenopausal osteoporosis","volume":"60","author":"Clemett","year":"2000","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0165","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1210\/endo.137.5.8612550","article-title":"Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance","volume":"137","author":"Yang","year":"1996","journal-title":"Endocrinology"},{"issue":"6652","key":"10.1016\/j.jsbmb.2014.03.003_bib0170","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/39645","article-title":"Molecular basis of agonism and antagonism in the oestrogen receptor","volume":"389","author":"Brzozowski","year":"1997","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0175","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1210\/endo.135.5.7956922","article-title":"Raloxifene preserves bone strength and bone mass in ovariectomized rats","volume":"135","author":"Turner","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"23","key":"10.1016\/j.jsbmb.2014.03.003_bib0185","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/mi.2011.011011","article-title":"Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis","volume":"17","author":"Genant","year":"2011","journal-title":"Menopause Int."},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0195","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","article-title":"The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1","volume":"80","author":"Lewis-Wambi","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis","volume":"4","author":"Komm","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"1\/2","key":"10.1016\/j.jsbmb.2014.03.003_bib0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jsbmb.2009.11.003","article-title":"Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens","volume":"118","author":"Chang","year":"2010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1210\/me.2012-1031","article-title":"Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM\/estrogen complexes","volume":"26","author":"Wardell","year":"2012","journal-title":"Mol. Endocrinol."},{"issue":"1\/2","key":"10.1016\/j.jsbmb.2014.03.003_bib0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mce.2008.01.027","article-title":"Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland","volume":"287","author":"Crabtree","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0220","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/en.2012-2038","article-title":"Inhibitory effects of a bazedoxifene\/conjugated equine estrogen combination on human breast cancer cells in vitro","volume":"154","author":"Song","year":"2013","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.jsbmb.2014.03.003_bib0225","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1210\/en.2012-1583","article-title":"Effects of the conjugated equine estrogen\/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice","volume":"153","author":"Song","year":"2012","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.jsbmb.2014.03.003_bib0230","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/GME.0b013e318252e46d","article-title":"Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys","volume":"19","author":"Ethun","year":"2012","journal-title":"Menopause"},{"issue":"12","key":"10.1016\/j.jsbmb.2014.03.003_bib0235","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1210\/en.2008-0817","article-title":"The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention","volume":"149","author":"Kharode","year":"2008","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0240","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.bone.2011.05.024","article-title":"Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats","volume":"49","author":"Komm","year":"2011","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0245","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/GME.0b013e31827ce57a","article-title":"Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model","volume":"20","author":"Ethun","year":"2013","journal-title":"Menopause"},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0250","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1158\/1078-0432.CCR-12-3771","article-title":"Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease","volume":"19","author":"Wardell","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.jsbmb.2014.03.003_bib0255","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0260","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0265","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2474-11-130","article-title":"Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis","volume":"11","author":"Christiansen","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","article-title":"Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study","volume":"76","author":"Palacios","year":"2013","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0275","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0280","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","article-title":"Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial","volume":"22","author":"de Villiers","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"13","key":"10.1016\/j.jsbmb.2014.03.003_bib0285","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1517\/14656560903127241","article-title":"Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy","volume":"10","author":"Gennari","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0290","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/endo.139.4.5902","article-title":"Effects of CP-336,156, a new, nonsteroidal estrogen agonist\/antagonist, on bone, serum cholesterol, uterus and body composition in rat models","volume":"139","author":"Ke","year":"1998","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0295","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/13543784.15.9.1091","article-title":"Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis","volume":"15","author":"Gennari","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"24","key":"10.1016\/j.jsbmb.2014.03.003_bib0300","first-page":"8683","article-title":"LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model","volume":"61","author":"Cohen","year":"2001","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2014.03.003_bib0305","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/gme.0b013e3181e84bb4","article-title":"Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes","volume":"18","author":"Goldstein","year":"2011","journal-title":"Menopause"},{"issue":"22","key":"10.1016\/j.jsbmb.2014.03.003_bib0315","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0320","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1210\/endo.138.9.5358","article-title":"Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone","volume":"138","author":"Willson","year":"1997","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0325","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1517\/13543780902953715","article-title":"Ospemifene use in postmenopausal women","volume":"18","author":"Gennari","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0330","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0335","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09513590410001672197","article-title":"Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women","volume":"18","author":"Komi","year":"2004","journal-title":"Gynecol. Endocrinol."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00042192-200512020-00015","article-title":"Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women","volume":"12","author":"Komi","year":"2005","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0350","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/gme.0b013e31826d36ba","article-title":"One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus","volume":"20","author":"Simon","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0355","unstructured":"K. Traynor, Pharmacy News Ospemifene approved for postmenopausal problem. American Society of Health-System Pharmacists web site, American Society of Health-System Pharmacists, http:\/\/www.ashp.org\/menu\/News\/PharmacyNews\/NewsArticle.aspx?id=3868 (accessed 28.01.14)."},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0360","series-title":"Osphena (package insert)","year":"2013"},{"issue":"23","key":"10.1016\/j.jsbmb.2014.03.003_bib0365","first-page":"8412","article-title":"Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer","volume":"61","author":"Suh","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0370","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1517\/13543784.15.3.317","article-title":"Arzoxifene: the development and clinical outcome of an ideal SERM","volume":"15","author":"Munster","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.jsbmb.2014.03.003_bib0375","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1021\/jm970167b","article-title":"Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator","volume":"40","author":"Palkowitz","year":"1997","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.jsbmb.2014.03.003_bib0380","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1210\/endo.139.11.6307","article-title":"LY353381 \u00d7 HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1\u201334)","volume":"139","author":"Sato","year":"1998","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)37755-9","article-title":"LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo","volume":"287","author":"Sato","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0390","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2008-2143","article-title":"Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass","volume":"94","author":"Bolognese","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"31","key":"10.1016\/j.jsbmb.2014.03.003_bib0395","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1200\/JCO.2006.09.5992","article-title":"Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer","volume":"25","author":"Deshmane","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0400","unstructured":"Lilly reports on outcome of phase III study of arzoxifene. Based on preliminary phase III GJAD study results, Lilly concludes arzoxifene's clinical profile does not support regulatory submission (press release). Eli Lilly and Company web site. https:\/\/investor.lilly.com\/releasedetail.cfm?ReleaseID=403905 (accessed 28.01.14)."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200666020-00005","article-title":"Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women","volume":"66","author":"Vogelvang","year":"2006","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3835(94)90364-6","article-title":"Preclinical data for Droloxifene","volume":"84","author":"Hasmann","year":"1994","journal-title":"Cancer Lett."},{"issue":"4 Suppl.","key":"10.1016\/j.jsbmb.2014.03.003_bib0415","doi-asserted-by":"crossref","first-page":"175S","DOI":"10.1016\/8756-3282(95)00290-T","article-title":"Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats","volume":"17","author":"Chen","year":"1995","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/8756-3282(95)00346-2","article-title":"Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats","volume":"17","author":"Ke","year":"1995","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0425","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/OGX.0b013e31816400d7","article-title":"Selective estrogen receptor modulators: an update on recent clinical findings","volume":"63","author":"Shelly","year":"2008","journal-title":"Obstet. Gynecol. Surv."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015229630260","article-title":"Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER\/PgR-positive advanced breast cancer","volume":"73","author":"Buzdar","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0435","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/13697130500117946","article-title":"Urogenital effects of selective estrogen receptor modulators: a systematic review","volume":"8","author":"Albertazzi","year":"2005","journal-title":"Climacteric"},{"issue":"12","key":"10.1016\/j.jsbmb.2014.03.003_bib0440","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1021\/jm00132a006","article-title":"Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent","volume":"32","author":"McCague","year":"1989","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.jsbmb.2014.03.003_bib0445","first-page":"5851","article-title":"Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer","volume":"51","author":"Chander","year":"1991","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0450","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/jm00002a005","article-title":"Rationally designed analogues of tamoxifen with improved calmodulin antagonism","volume":"38","author":"Hardcastle","year":"1995","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.jsbmb.2014.03.003_bib0455","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1210\/endo.139.12.6343","article-title":"Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats","volume":"139","author":"Nuttall","year":"1998","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0460","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-003-0733-6","article-title":"A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced\/metastatic breast cancer resistant to tamoxifen","volume":"53","author":"Johnston","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0465","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","article-title":"ICI 182,780 (Faslodex): development of a novel, pure antiestrogen","volume":"89","author":"Howell","year":"2000","journal-title":"Cancer"},{"issue":"1\u20136","key":"10.1016\/j.jsbmb.2014.03.003_bib0470","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0022-4731(88)90086-6","article-title":"Biology and mode of action of pure antioestrogens","volume":"30","author":"Wakeling","year":"1988","journal-title":"J. Steroid Biochem."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0475","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bjc.1996.357","article-title":"Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer","volume":"74","author":"Howell","year":"1996","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0480","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.112R007","article-title":"Steroidal pure antioestrogens","volume":"112","author":"Wakeling","year":"1987","journal-title":"J. Endocrinol."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0485","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.12-7-774","article-title":"Fulvestrant (Faslodex) \u2013 how to make a good drug better","volume":"12","author":"Robertson","year":"2007","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.jsbmb.2014.03.003_bib0490","first-page":"6739","article-title":"Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer","volume":"61","author":"Robertson","year":"2001","journal-title":"Cancer Res."},{"issue":"Pt 4","key":"10.1016\/j.jsbmb.2014.03.003_bib0495","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1242\/jcs.106.4.1377","article-title":"The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling","volume":"106","author":"Dauvois","year":"1993","journal-title":"J. Cell Sci."},{"issue":"17","key":"10.1016\/j.jsbmb.2014.03.003_bib0500","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1073\/pnas.87.17.6883","article-title":"Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization","volume":"87","author":"Fawell","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1677\/erc.0.0070017","article-title":"Similarities and distinctions in the mode of action of different classes of antioestrogens","volume":"7","author":"Wakeling","year":"2000","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0510","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1677\/joe.0.1350239","article-title":"Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys","volume":"135","author":"Dukes","year":"1992","journal-title":"J. Endocrinol."},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0515","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1210\/endo.133.6.8243306","article-title":"The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats","volume":"133","author":"Gallagher","year":"1993","journal-title":"Endocrinology"},{"issue":"16","key":"10.1016\/j.jsbmb.2014.03.003_bib0520","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1200\/JCO.2002.10.058","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.jsbmb.2014.03.003_bib0525","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0530","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.11468","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials","volume":"98","author":"Robertson","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0535","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cncr.21163","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials","volume":"104","author":"Howell","year":"2005","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0540","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1200\/JCO.2004.02.112","article-title":"Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial","volume":"22","author":"Howell","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.jsbmb.2014.03.003_bib0545","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0550","series-title":"Faslodex (package insert)","year":"2012"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0555","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0022-3565(24)38923-2","article-title":"Molecular mechanisms of selective estrogen receptor modulator (SERM) action","volume":"295","author":"Dutertre","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0560","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0565","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ijc.10302","article-title":"Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice","volume":"99","author":"Gutman","year":"2002","journal-title":"Int. J. Cancer"},{"issue":"1\u20135","key":"10.1016\/j.jsbmb.2014.03.003_bib0570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0960-0760(01)00139-X","article-title":"EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium","volume":"79","author":"Labrie","year":"2001","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1\/2","key":"10.1016\/j.jsbmb.2014.03.003_bib0575","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jsbmb.2004.05.009","article-title":"The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats","volume":"92","author":"Goss","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0580","series-title":"Abstract from the: Annual Meeting of the Endocrine Society","article-title":"RAD-1901, a novel SERM, has efficacy in an animal model of vasomotor symptoms","author":"Hattersley","year":"2007"},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0585","series-title":"Abstract from the: Annual Meeting of the Endocrine Society","article-title":"RAD1901, a novel selective estrogne receptor modulator (SERM), demonstrates evidence of efficacy on postmenopausal hot flashes in an early phase human study","author":"O\u2019Dea","year":"2010"},{"issue":"10","key":"10.1016\/j.jsbmb.2014.03.003_bib0590","first-page":"3166","article-title":"A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-o l hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats","volume":"7","author":"Greenberger","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.jsbmb.2014.03.003_bib0595","doi-asserted-by":"crossref","first-page":"12819","DOI":"10.1074\/jbc.M709936200","article-title":"A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells","volume":"283","author":"Mao","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"53","key":"10.1016\/j.jsbmb.2014.03.003_bib0600","doi-asserted-by":"crossref","first-page":"41863","DOI":"10.1074\/jbc.M110.183723","article-title":"A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}","volume":"285","author":"Kretzer","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.jsbmb.2014.03.003_bib0605","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/11316000-000000000-00000","article-title":"Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms","volume":"27","author":"Archer","year":"2010","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.jsbmb.2014.03.003_bib0610","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/me.2008-0366","article-title":"Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination","volume":"23","author":"Berrodin","year":"2009","journal-title":"Mol. Endocrinol."},{"issue":"Suppl. 2","key":"10.1016\/j.jsbmb.2014.03.003_bib0615","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0378-5122(00)00110-9","article-title":"Recent insights into the varying activity of estrogens","volume":"34","author":"Dey","year":"2000","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.jsbmb.2014.03.003_bib0620","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/mol.112.084228","article-title":"Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes","volume":"83","author":"Liu","year":"2013","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"10.1016\/j.jsbmb.2014.03.003_bib0625","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/jwh.2011.3448","article-title":"The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms","volume":"21","author":"Kagan","year":"2012","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0630","unstructured":"Pfizer Inc announces FDA approval of DUAVEE\u2122 (conjugated estrogens\/bazedoxifene) for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and the prevention of postmenopausal osteoporosis (press release). Pfizer web site. http:\/\/www.pfizer.com\/news\/press-release\/press-release-archive-detail\/pfizer_inc_announces_fda_approval_of_duaveetm_conjugated_estrogens_bazedoxifene_for_the_treatment_of_moderate_to_severe_vasomotor_symptoms_hot_flashes_associated_with_menopause_and_the_prevention_of_postmenopausal_osteoporosis (accessed 27.01.14)."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1933719111431002","article-title":"Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation","volume":"20","author":"Oliva","year":"2013","journal-title":"Reprod. Sci."},{"issue":"4","key":"10.1016\/j.jsbmb.2014.03.003_bib0640","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/en.2008-1210","article-title":"Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland","volume":"150","author":"Peano","year":"2009","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0645","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.jsbmb.2014.03.003_bib0650","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0655","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0660","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil. Steril."},{"issue":"3","key":"10.1016\/j.jsbmb.2014.03.003_bib0665","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.jsbmb.2014.03.003_bib0670","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"issue":"Suppl. 1","key":"10.1016\/j.jsbmb.2014.03.003_bib0675","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jsbmb.2014.03.003_bib0680","doi-asserted-by":"crossref","first-page":"584549","DOI":"10.1155\/2013\/584549","article-title":"Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability","volume":"2013","author":"Kushwaha","year":"2013","journal-title":"Biomed. Res. Int."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076014000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076014000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:45:53Z","timestamp":1760744753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076014000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":136,"alternative-id":["S0960076014000636"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2014.03.003","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of current and emerging SERMs","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2014.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}